Potent Dmt-Tic pharmacophoric δ- and μ-opioid receptor antagonists

Journal of Medicinal Chemistry

Volumn 48, Issue 25, 2005, Pages 8035-8044

  Li, Tingyou ^a   Fujita, Yoshio ^a   Shiotani, Kimitaka ^a   Miyazaki, Anna ^a   Tsuda, Yuko ^a   Ambo, Akihiro ^b   Sasaki, Yusuke ^b   Jinsmaa, Yunden ^d   Marczak, Ewa ^d   Bryant, Sharon D ^d   Salvadori, Severe ^c   Lazarus, Lawrence H ^d   Okada, Yoshio ^a  

^a KOBE GAKUIN UNIVERSITY   (Japan)

^b TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

^c UNIVERSITY OF FERRARA   (Italy)

^d NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,10 BIS(2',6' DIMETHYLTYROSYL 1,2,3,4 TETRAHYDROISOQUINOLINE 3 CARBOXYLAMINOAMINO)DECANE; 1,4 BIS(2',6' DIMETHYLTYROSYL 1,2,3,4 TETRAHYDROISOQUINOLINE 3 CARBOXYLAMINOAMINO)BUTANE; 1,6 BIS(2',6' DIMETHYLTYROSYL 1,2,3,4 TETRAHYDOISOQUINOLINE 3 CARBOXYLAMINOAMINO)HEXANE; 1,6 BIS(N,N DIMETHYL 2',6' DIMETHYLTYROSYL 1,2,3,4 TETRAHYDROISOQUINOLINE 3 CARBOXYLAMINOHEXANE) 2(1H) PYRAZINONE; 2',6' DIMETHYLTYROSYL 1,2,3,4 TETRAHYDROISOQUINOLINE 3 CARBOXYLIC ACID DERIVATIVE; 3 (2',6' DIMETHYLTYROSYL 1,2,3,4 TETRAHYDROISOQUINOLINE 3 CARBOXYLAMINOBUTYL) 6 (2',6' DIMETHYLTYROSYL 1,2,3,4 TETRAHYDROISOQUINOLINE 3 CARBOXYLAMINOPROPYL) 2(1H) PYRAZINONE; 3 (2',6' DIMETHYLTYROSYL 1,2,3,4 TETRAHYDROISOQUINOLINE 3 CARBOXYLAMINOETHYL) 6 (2',6' DIMETHYLTYROSYL 1,2,3,4 TETRAHYDROISOQUINOLINE 3 CARBOXYLAMINOBUTYL) 2(1H) PYRAZINONE; 3 (2',6' DIMETHYLTYROSYL 1,2,3,4 TETRAHYDROISOQUINOLINE 3 CARBOXYLAMINOPROPYL) 6 (2',6' DIMETHYLTYROSYL 1,2,3,4 TETRAHYDROISOQUINOLINE 3 CARBOXYLAMINOBUTYL) 2(1H) PYRAZINONE; 3,6 BIS(2',6' DIMETHYLTYROSYL 1,2,3,4 TETRAHYDROISOQUINOLINE 3 CARBOXYLAMINOBUTYL) 2(1H) PYRAZINONE; 3,6 BIS(2',6' DIMETHYLTYROSYL 1,2,3,4 TETRAHYDROISOQUINOLINE 3 CARBOXYLAMINOETHYL) 2(2H) PYRAZINONE; 3,6 BIS(2',6' DIMETHYLTYROSYL 1,2,3,4 TETRAHYDROISOQUINOLINE 3 CARBOXYLAMINOMETHYL) 2(1H) PYRAZINONE; 3,6 BIS(2',6' DIMETHYLTYROSYL 1,2,3,4 TETRAHYDROISOQUINOLINE 3 CARBOXYLAMINOPROPYL) 2(1H) PYRAZINONE; 3,6 BIS(N,N DIMETHYL 2',6' DIMETHYLTYROSYL 1,2,3,4 TETRAHYDROISOQUINOLINE 2 CARBOXYLAMINOPROPYL) 2(1H) PYRAZINONE; ALKANE; ALKANEDIAMINE; DELTA OPIATE RECEPTOR; MU OPIATE RECEPTOR; OPIATE ANTAGONIST; PYRAZINONE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BIOASSAY; COVALENT BOND; DRUG ACTIVITY; DRUG RECEPTOR BINDING; IN VITRO STUDY; PHARMACOPHORE; RECEPTOR BLOCKING; RECEPTOR SENSITIVITY;

ANIMALS; BINDING, COMPETITIVE; BRAIN; DIAMINES; DIPEPTIDES; GUINEA PIGS; ILEUM; LIGANDS; MALE; MICE; MUSCLE, SMOOTH; PEPTIDES; PYRAZINES; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, MU; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAHYDROISOQUINOLINES; VAS DEFERENS;

EID: 29144453259     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050377l     Document Type: Article

References (54)

1. 50, concentration required for 50% inhibition of the electrically induced contraction in muscle derived from a dose-response curve; MVD, mouse vas deferens; NMR, nuclear magnetic resonance; PyBOP, benzoltriazol-1-yloxytrispyrrolidinophosphonium hexafluorphosphate; RP-HPLC, reverse-phase high performance liquid chromatography; TFA, trifluoroacetic acid; Tic, 1,2,3,4-tetrahydroisoquinoline-3-carboxyl acid; TLC, thin-layer chromatography; Z, benzyloxycarbonyl.
2. Temussi, P. A.; Salvadori, S.; Amodeo, P.; Bianchi, C.; Guerrini, R.; Tomatis, R.; Lazarus, L. H.; Picone, D.; Tancredi, T. Selective opioid dipeptides. Biochem. Biophys. Res. Commun. 1994, 198, 933-939.
3. Salvadori, S.; Attila, M.; Balboni, G.; Bianchi, C.; Bryant, S. D.; Crescenzi, O.; Guerrini, R.; Picone, D.; Tancredi, T.; Temussi, P. A.; Lazarus, L. H. δ Opioidmimetic antagonists: Prototypes for designing a new generation of ultraselective opioid peptides. Mol. Med. 1995, 1, 678-689.
4. Capasso, A.; Guerrini, R.; Balboni, G.; Sorrentino, L.; Temussi, P.; Lazarus, L. H.; Bryant, S. D.; Salvadori, S. Dmt-Tic-OH, a highly selective and potent δ-opioid dipeptide receptor antagonist after systemic administration in the mouse. Life Sci. 1996, 59, PL93-98.
5. (a) Lazarus, L. H.; Bryant, S. D.; Cooper, P. S.; Guerrini, R.; Balboni, G.; Salvadori, S. Design of δ-opioid peptide antagonists for emerging drug applications. Drug Discovery Today 1998, 3, 284-294.
6. (b) Bryant, S. D.; Jinsmaa, Y.; Salvadori, S.; Okada, Y.; Lazarus, L. H. Dmt and opioid peptides: A potent alliance. Biopolymers (Pept. Sci.) 2003, 71, 86-102.
7. (a) Salvadori, S.; Balboni, G.; Guerrini, R.; Tomatis, R.; Bianchi, C.; Bryant, S. D.; Copper, P. S.; Lazarus, L. H. Evolution of the Dmt-Tic pharmacophore: N-Terminal methylated derivatives with extraordinary δ opioid antagonist activity. J. Med. Chem. 1997, 40, 3100-3108.
8. (b) Salvadori, S.; Guerrini, R.; Balboni, G.; Bianchi, C.; Bryant, S. D.; Copper, P. S.; Lazarus, L. H. Further studies on the Dmt-Tic pharmacophore: Hydrophobic substituents at the C-terminus endow δ antagonists to manifest μ agonism or μ antagonism. J. Med. Chem. 1999, 42, 5010-5019.
9. Balboni, G.; Salvadori, S.; Guerrini, R.; Bianchi, C.; Santagata, V.; Calliendo, G.; Bryant, S. D.; Lazarus, L. H. Opioid pseudopeptides containing heteroaromatic or heteroaliphatic nuclei. Peptides 2000, 21, 1663-1671.
10. Capasso, A.; Amodeo, P.; Balboni, G.; Guerrini, R.; Lazarus, L. H.; Temussi, P. A.; Salvadori, S. Design of μ selective opioid dipeptide antagonists. FEBS Lett. 1997, 417, 141-144.
11. (a) Balboni, G.; Guerrini, R.; Salvadori, S.; Bianchi, C.; Rizzi, D.; Bryant, S. D.; Lazarus, L. H. Evaluation of the Dmt-Tic pharmacophore: Conversion of a potent δ-opioid receptor antagonist into a potent δ-agonist and ligands with mixed properties. J. Med. Chem. 2002, 45, 713-720.
12. (b) Balboni, G.; Salvadori, S.; Guerrini, R.; Negri, L.; Giannini, E.; Bryant, S. D.; Jinsmaa, Y.; Lazarus, L. H. Synthesis and opioid activity of N,N-dimethyl-Dmt-Tic-NH-CH(R)-R′ analogues: Acquisition of potent δ antagonism. Bioorg. Med. Chem. 2003, 11, 5435-5441.
13. (c) Balboni, G.; Salvadori, S.; Dal Piaz, A.; Bortolotti, F.; Argazzi, R.; Negri, L.; Lattanzi, R.; Bryant, S. D.; Jinsmaa, Y.; Lazarus, L. H. Highly selective fluorescent analogue of the potent δ-opioid receptor antagonist Dmt-Tic. J. Med. Chem. 2004, 47, 6541-6546.
14. Okada, Y.; Tsuda, Y.; Fujita, Y.; Yokoi, T.; Sasaki, Y.; Ambo, A.; Konishi, R.; Nagata, M.; Salvadori, S.; Jinsmaa, Y.; Bryant S. D.; Lazarus, L. H. Unique high-affinity synthetic μ-opioid receptor agonists with central- and systemic-mediated analgesia. J. Med. Chem. 2003, 46, 3201-3209.
15. n]-2(1H)-pyrazinone with central-mediated analgesia. J. Med. Chem. 2004, 47, 2599-2610.
16. Stromberg, M. F.; Casale, M.; Volpicelli, L.; Volpicelli, J. R.; O'Brien, C. P. A comparison of the effects of the opioid antagonists naltrexone, naltrindole, and β-funaltrexamine on ethanol consumption in the rat. Alcohol 1998, 15, 281-289.
17. (a) Portoghese, P. S. Bivalent ligands and the message-address concept in the design of selective opioid receptor antagonists. Trends Pharmacol. Sci. 1989, 10, 230-235.
18. (b) Portoghese, P. S. The role of concepts in structure-activity relationship studies of opioid ligands. J. Med. Chem. 1992, 35, 1927-1937.
19. (c) Portoghese P. S. From models to molecules: Opioid receptor dimers, bivalent ligands, and selective opioid receptor probes. J. Med. Chem. 2001, 44, 2259-2269.
20. Lipkowski, A. W.; Konecka, A. M.; Sroczyńska, I. Double-enkephalins-synthesis, activity on guinea-pig ileum, and analgesic effect. Peptides 1982, 3, 697-700.
21. Lazarus, L. H.; Guglietta, A.; Wilson, W. E.; Irons, B. J.; Castiglione, R. Dimeric dermorphin analogues as μ-receptor probes on rat brain membranes. Correlation between central μ-receptor potency and suppression of gastric acid secretion. J. Biol. Chem. 1989, 264, 354-362.
22. (a) Horan, P. J.; Mattia, A.; Bilsky, E. J.; Weber, S.; Davis, T. P.; Yamamura, H. I.; Malatynska, E.; Appleyard, S. M.; Slaninova, J.; Misicka, A.; Lipkowski, A. W.; Hruby, V. J.; Porreca, F. Antinociceptive profile of biphalin, a dimeric enkephalin analog. J. Pharmacol. Exp. Ther. 1993, 265, 1446-54.
23. (b) Hruby, V. J.; Davis, T. P.; Plot, R.; Bartosz-Bechowski, H.; Misicka, A.; Lipkowski, A.; Sharma, S. D.; Li, G.; Bonner, G.; Meyer, J.-P.; Patel, D.; Qian, X.; Romanowski, M.; Yamamura, H. I.; Porreca, F.; O'Brien, D. F. A systematic investigation of factors that enhance penetration of peptides across the blood-brain barrier. In Peptides: Chemistry, Structure and Biology; Kaumaya, P. T. P., Hodges, R. S., Eds.; Mayflower Scientific Ltd.: Kingswinford, England, 1996; pp 154-156.
24. (c) Abbruscato, T. J.; Thomas, S. A.; Hruby, V. J.; Davis, T. P. Brain and spinal cord distribution of biphalin: Correlation with opioid receptor density and mechanism of CNS entry. J. Neurochem. 1997, 69, 1236-1245.
25. (d) Misicka, A.; Lipkowski, A. W.; Horvath, R.; Davis, P.; Porreca, F.; Yamamura, H. L; Hruby, V. J. Structure-activity relationship of biphalin. The synthesis and biological activities of new analogues with modifications in position 3 and 4. Life Sci. 1997, 60, 1263-1269.
26. (e) Yamazaki, M.; Suzuki, T.; Narita, M.; Lipkowski, A. W. The opioid peptide analogue biphalin induces less physical dependence than morphine. Life Sci. 2001, 69, 1023-1028.
27. Weltrowska, G.; Lemieux, G.; Chung, N. N.; Schiller, P. W. A chimeric opioid peptide with mixed μ agonist/δ antagonist properties. J. Pept. Res. 2004, 63, 63-68.
28. (a) Portoghese, P. S.; Lipkowski, A. W.; Takimori, A. E. Binaltorphimine and nor-binaltorphimine, potent and selective κ-opioid receptor antagonists. Life Sci. 1987, 40, 1287-1292.
29. (b) Takimori, A. E.; Ho, B. Y.; Naeseth, J. S.; Portoghese, P. S. Norbinaltrophimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays. J. Pharmacol. Exp. Ther. 1988, 246, 255-258.
30. 3. Bioorg. Med. Chem. Lett. 2005, 15, 599-602.
31. Igarashi, K.; Murabayashi, Y.; Hotta, K.; Kitamura, Y.; Kasuya, F.; Shiotani, K.; Li, T.; Miyazaki, A.; Tsuda, Y.; Okada, Y.; Fukushima, S. Application of liquid chromatography-tandem mass spectrometry for the determination of opioidmimetics in the brain dialysates from rats treated with opioidmimetics intraperitoneally. J. Chromatography B 2004, 806, 53-57.
32. Dygos, J. H.; Yonan, E. E.; Scaros, M. G.; Goodmonson, O. J.; Getman, D. P.; Periana, R. A.; Beck, G. R. A convenient asymmetric synthesis of the unnatural amino acid 2,6-dimethyl-L-tyrosine. Synthesis 1992, 8, 741-743.
33. Callahan, J. F.; Ashton-Shue, D.; Bryan, H. G.; Bryan, W. M.; Heckman, G. D.; Kinter, L. B.; McDonald, J. E.; Moore, M. L.; Schmidt, D. B.; Silvestri, J. S.; Stassen, F. L.; Sulat, L.; Yim, N. C. F.; Huffman, W. F. Structure-activity relationships of novel vasopressin antagonists containing C-terminal diaminoalkanes and (aminoalkyl)guanidines. J. Med. Chem. 1989, 32, 391-396.
34. Okada, Y.; Fukumizu, A.; Takahasi, M.; Yamazaki, J.; Yokoi, T.; Tsuda, Y.; Bryant, S. D.; Lazarus, L. H. Amino acids and peptides. LVI. Synthesis of pyrazinone ring-containing opioid mimetics and examination of their opioid receptor binding activity. Tetrahedron 1999, 55, 14391-14406.
35. Fujita, Y.; Tsuda, Y.; Li, T.; Motoyama, T.; Takahashi, M.; Shimizu, Y.; Yokoi, T.; Sasaki, Y.; Ambo, A.; Kita, A.; Jinsmaa, Y.; Bryant, S. D.; Lazarus, L. H.; Okada, Y. Development of potent bifunctional endomorphin-2 analogs with mixed μ-/δ-opioid agonist and δ-opioid antagonist properties. J. Med. Chem. 2004, 47, 3591-3599.
36. (a) Kramer, T. H.; Shook, J. E.; Kazmierski, W.; Ayres, E. A.; Wire, W. S.; Hruby, V. J.; Burks, T. F. Novel peptidic mu opioid antagonists: Pharmacologic characterization in vitro and in vivo. J. Pharmacol. Exp. Ther. 1989, 249, 544-551.
37. 2] dermorphin(1-4) analogs with μ-opioid receptor antagonist activity. Chem. Pharm. Bull. 2002, 50, 1401-1403.
38. (a) Ward, S. J.; Portoghese, P. S.; Takemori, A. E. Pharmacological characterization in vivo of the novel opiate, β-funaltrexamine. J. Pharmacol. Exp. Ther. 1982, 220, 494-498.
39. (b) Comer, S. D.; Burke, T. F.; Lewis, J. W.; Woods, J. H. Clocinnamox: A novel, systemically active, irreversible opioid antagonist. J. Pharmacol. Exp. Ther. 1992, 262, 1051-1056.
40. (c) Xu, J. Y.; Seyed-Mozaffari, A.; Archer, S.; Bidlack, J. M. N-cyclobutymethyl analogue of normorphinone, N-CBM-TAMO: A short-term opioid agonist and long-term mu-selective irreversible opioid antagonist. J. Pharmacol. Exp. Ther. 1996, 279, 539-547.
41. (d) Derrick, I.; Neilan, C. L.; Andes, J.; Husbands, S. M.; Woods, J. H.; Traynor, J. R.; Lewis, J. W. 3-Deoxyclocinnamox: The first high-affinity, nonpeptide μ-opioid antagonist lacking a phenolic hydroxyl group. J. Med. Chem. 2000, 43, 3348-3350.
42. Minami, M.; Satoh, M. Molecular biology of the opioid receptors: Structures, functions and distributions. Neurosci. Res. 1995, 23, 121-45.
43. Bryant, S. D.; Salvadori, S.; Okada, Y.; Takahashi, M.; Sasaki, Y.; Lazarus, L. H. Computational chemistry and opioid-mimetics: Receptor ligand interaction of three classes of biologically potent peptides. In Peptides 2000; Martinez, J., Fehrentz, J.-A., Eds.; Editions EDK: Paris, 2001; pp 407-408.
44. 3H]β-funaltrexamine covalent binding in the cloned rat μ opioid receptor. J. Biol. Chem. 1996, 271, 21422-21429.
45. Marie, N.; Lecoq, I.; Jauzac, P.; Allouche, S. Differential sorting of human δ-opioid receptors after internalization by peptide and alkaloid agonists. J. Biol. Chem. 2003, 278, 22795-22804.
46. 4-enkephalin analogues. Delta receptors in rat brain are different from those in mouse vas deferens. FEBS Lett. 1987, 222, 71-74.
47. 4-enkephalin analogue, suppresses μ receptor-mediated thermal analgesia by morphine. FEBS Lett. 1988, 233, 289-293.
48. (c) Vaughn, L. K.; Wire, W. S.; Davis, P.; Shimohigashi, Y.; Toth, G.; Knapp, R. J.; Hruby, V. J.; Burks, T. F.; Yamamura, H. I. Differentiation between rat brain and mouse vas deferens δ opioid receptors. Eur. J. Pharmacol. 1990, 177, 99-101.
49. Banks, W. A.; Kastin, A. J. Peptide transport systems for opiates across the blood-brain barrier. Am. J. Physiol. 1990, 259, E1-E10.
50. (a) Lazarus, L. H.; Salvadori, S.; Santagada, V.; Tomatis, R.; Wilson, W. E. Function of negative charge in the "address domain" of deltorphins. J. Med. Chem. 1991, 34, 1350-1355.
51. (b) Lazarus, L. H.; Salvadori, S.; Attila, M.; Grieco, P.; Bundy, D. M.; Wilson, W. E.; Tomatis, R. Interaction of deltorphin with opioid receptors: Molecular determinants for affinity and selectivity. Peptides 1993, 14, 21-28.
52. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
53. Sasaki, Y.; Sasaki, A.; Niizuma, H.; Goto, H.; Ambo, A. Endomorphin 2 analogues containing Dmp residue as an aromatic amino acid surrogate with high μ-opioid receptor affinity and selectivity. Bioorg. Med. Chem. 2003, 11, 675-678.
54. Arunlakshana, Q.; Schild, H. O. Some quantitative uses of drug antagonists. Br. J. Pharmcol. 1959, 14, 48-58.